Top

World Journal of Urology

Published in:

Open Access 01-01-2022 | Nephrectomy | Original Article

Polyethylene glycol-coated collagen patch (hemopatch^®) in open partial nephrectomy

Authors: Michael Staehler, S. Rodler, M. Schott, J. Casuscelli, C. Stief, A. Spek, B. Schlenker

Published in: World Journal of Urology | Issue 1/2022

Abstract

Purpose

To describe the results of a polyethylene glycol-coated collagen patch, Hemopatch^® on blood loss, surgical time and renal function in partial nephrectomy (PN) for renal cell carcinoma (RCC).

Methods

Out of a single surgeon cohort of n = 565 patients undergoing conventional open PN (CPN) between 01/2015 and 12/2017 at the University of Munich a consecutive subgroup (n = 42) was operated on using a polyethylene glycol-coated collagen-based sealant Hemopatch^® (Baxter International Inc., Deerfield, IL, USA) (HPN).

Results

Median age was 65.2 years (range 12.7–95.2) with median follow-up of 9.43 months (0.03–49.15). Baseline renal function (CKD-EPI) was 78.56 ml/min/1.73 m² (range 20.38–143.09) with a non-significant decline to 74.78 ml/min/1.73 m² (range 3.75–167.74) at follow-up.

In CPN 46% had low complexity, 33% moderate complexity and 20% high complexity lesions with 33% low, 40% moderate and 27% high complexity masses in HPN.

Median tumor size was 4.3 cm (range 1–38 cm) in CPN with 4.8 cm (range 3.8–18.3 cm) with HPN, p = 0.293. Median blood loss and duration of surgery was significantly lower in the HPN group vs. CPN (146 ml ± 195 vs. 114 ml ± 159 ml; p = 0.021; 43 min ± 27 for HPN vs. 53 min ± 49; p = 0.035) with no difference in clamping time (12.6 min ± 8.6 for HPN vs. 12.0 min ± 9.5; p = 0.701).

Conclusions

Hemopatch^® supported renoraphy shows promising results compared to standard renoraphy in PN. No side effects were seen. Further studies should evaluate the prevention of arterio-venous or urinary fistulas. In complex partial nephrectomies Hemopatch^® supported renoraphy should be considered.

Ljungberg B, Albiges L, Abu-Ghanem Y, Bensalah K, Dabestani S, Fernandez-Pello S et al (2019) European association of urology guidelines on renal cell carcinoma: the 2019 update. Eur Urol 75(5):799–810CrossRef

Van Poppel H, Da Pozzo L, Albrecht W, Matveev V, Bono A, Borkowski A, Colombel M, Klotz L, Skinner E, Keane T, Marreaud S, Collette S, Sylvester R (2011) A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. Eur Urol 59(4):543–552. https://doi.org/10.1016/j.eururo.2010.12.013CrossRefPubMed

Weight CJ, Lieser G, Larson BT, Gao T, Lane BR, Campbell SC, Gill IS, Novick AC, Fergany AF (2010) Partial nephrectomy is associated with improved overall survival compared to radical nephrectomy in patients with unanticipated benign renal tumours. Eur Urol 58(2):293–298. https://doi.org/10.1016/j.eururo.2010.04.033CrossRefPubMed

Dabestani S, Beisland C, Stewart GD, Bensalah K, Gudmundsson E, Lam TB, Gietzmann W, Zakikhani P, Marconi L, Fernandez-Pello S, Monagas S, Williams SP, Torbrand C, Powles T, Van Werkhoven E, Meijer R, Volpe A, Staehler M, Ljungberg B, Bex A (2018) Long-term outcomes of follow-up for initially localised clear cell renal cell carcinoma: RECUR database analysis. Eur Urol Focus. https://doi.org/10.1016/j.euf.2018.02.010CrossRefPubMed

Ljungberg B, Hedin O, Lundstam S, Warnolf A, Mandahl Forsberg A, Hjelle KM, Stief CG, Borlinghaus C, Beisland C, Staehler M (2016) Nephron sparing surgery associated with better survival than radical nephrectomy in patients treated for unforeseen benign renal tumors. Urology 93:117–123. https://doi.org/10.1016/j.urology.2016.01.037CrossRefPubMed

Kutikov A, Uzzo RG (2009) The R.E.N.A.L. nephrometry score: a comprehensive standardized system for quantitating renal tumor size, location and depth. J Urol 182(3):844–853. https://doi.org/10.1016/j.juro.2009.05.035CrossRefPubMed

Chang X, Liu T, Zhang F, Qian C, Ji C, Zhao X, Liu G, Guo H (2015) The comparison of R.E.N.A.L., PADUA and centrality index score in predicting perioperative outcomes and complications after laparoscopic radio frequency ablation of renal tumors. J Urol 194(4):897–902. https://doi.org/10.1016/j.juro.2015.03.095CrossRefPubMed

Siemer S, Lahme S, Altziebler S, Machtens S, Strohmaier W, Wechsel HW, Goebell P, Schmeller N, Oberneder R, Stolzenburg JU, Becker H, Luftenegger W, Tetens V, Van Poppel H (2007) Efficacy and safety of TachoSil as haemostatic treatment versus standard suturing in kidney tumour resection: a randomised prospective study. Eur Urol 52(4):1156–1163. https://doi.org/10.1016/j.eururo.2007.04.027CrossRefPubMed

Lewis KM, Ikeme S, Olubunmi T, Kuntze CE (2018) Clinical effectiveness and versatility of a sealing hemostatic patch (HEMOPATCH) in multiple surgical specialties. Expert Rev Med Devices 15(5):367–376. https://doi.org/10.1080/17434440.2018.1464909CrossRefPubMed

10.

Imkamp F, Tolkach Y, Wolters M, Jutzi S, Kramer M, Herrmann T (2015) Initial experiences with the Hemopatch(R) as a hemostatic agent in zero-ischemia partial nephrectomy. World J Urol 33(10):1527–1534. https://doi.org/10.1007/s00345-014-1404-4CrossRefPubMed

11.

Fingerhut A, Uranues S, Ettorre GM, Felli E, Colasanti M, Scerrino G, Melfa GI, Raspanti C, Gulotta G, Meyer A, Oberhoffer M, Schmoeckel M, Weltert LP, Vignolini G, Salvi M, Masieri L, Vittori G, Siena G, Minervini A, Serni S, Carini M (2014) European initial hands-on experience with HEMOPATCH, a novel sealing hemostatic patch: application in general, gastrointestinal, biliopancreatic, cardiac, and urologic surgery. Surg Technol Int 25:29–35PubMed

12.

Ljungberg B, Bensalah K, Canfield S, Dabestani S, Hofmann F, Hora M, Kuczyk MA, Lam T, Marconi L, Merseburger AS, Mulders P, Powles T, Staehler M, Volpe A, Bex A (2015) EAU Guidelines on renal cell carcinoma: 2014 update. Eur Urol. https://doi.org/10.1016/j.eururo.2015.01.005CrossRefPubMed

13.

Escudier B, Porta C, Schmidinger M, Algaba F, Patard JJ, Khoo V, Eisen T, Horwich A, Group EGW (2014) Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. https://doi.org/10.1093/annonc/mdu259CrossRefPubMed

14.

Lee DJ, Hruby G, Benson MC, McKiernan JM (2010) Renal function and oncologic outcomes in nephron sparing surgery for renal masses in solitary kidneys. World J Urol. https://doi.org/10.1007/s00345-010-0576-9CrossRefPubMed

15.

Thompson RH, Lane BR, Lohse CM, Leibovich BC, Fergany A, Frank I, Gill IS, Blute ML, Campbell SC (2010) Every minute counts when the renal hilum is clamped during partial nephrectomy. Eur Urol 58(3):340–345. https://doi.org/10.1016/j.eururo.2010.05.047CrossRefPubMed

16.

Riggs SB, Larochelle JC, Belldegrun AS (2008) Partial nephrectomy: a contemporary review regarding outcomes and different techniques. Cancer J 14(5):302–307. https://doi.org/10.1097/PPO.0b013e31818675aeCrossRefPubMed

17.

Rane A, Rimington PD, Heyns CF, van der Merwe A, Smit S, Anderson C (2010) Evaluation of a hemostatic sponge (TachoSil) for sealing of the renal collecting system in a porcine laparoscopic partial nephrectomy survival model. J Endourol 24(4):599–603. https://doi.org/10.1089/end.2009.0453CrossRefPubMed

18.

Soria F, de Martino M, Leitner CV, Moschini M, Shariat SF, Klatte T (2017) Perioperative allogenic blood transfusion in renal cell carcinoma: risk factors and effect on long-term outcomes. Clin Genitourin Cancer 15(3):e421–e427. https://doi.org/10.1016/j.clgc.2016.12.002CrossRefPubMed

19.

Tonyali S, Koni A, Yazici S, Bilen CY (2017) The safety and efficacy of adjuvant hemostatic agents during laparoscopic nephron-sparing surgery: comparison of tachosil and floseal versus no hemostatic agents. Urol J 15(1):21–25. https://doi.org/10.22037/uj.v0i0.4090CrossRefPubMed

20.

Peyronnet B, Oger E, Khene Z, Verhoest G, Mathieu R, Roumiguie M, Beauval JB, Pradere B, Masson-Lecomte A, Vaessen C, Baumert H, Bernhard JC, Doumerc N, Droupy S, Bruyere F, De La Taille A, Roupret M, Bensalah K (2015) The use of hemostatic agents does not prevent hemorrhagic complications of robotic partial nephrectomy. World J Urol 33(11):1815–1820. https://doi.org/10.1007/s00345-015-1537-0CrossRefPubMed

Title: Polyethylene glycol-coated collagen patch (hemopatch®) in open partial nephrectomy
Authors: Michael Staehler
S. Rodler
M. Schott
J. Casuscelli
C. Stief
A. Spek
B. Schlenker
Publication date: 01-01-2022
Publisher: Springer Berlin Heidelberg
Keywords: Nephrectomy
Kidney Cancer
Kidney Cancer
Nephrectomy
Kidney Cancer
Nephrectomy
Published in: World Journal of Urology / Issue 1/2022
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-021-03827-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Polyethylene glycol-coated collagen patch (hemopatch^®) in open partial nephrectomy

Abstract

Purpose

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2022

Redefining the urologist’s role in kidney transplantation

Intravesical instillation of high molecular weight sodium hyaluronate in radiation-induced cystitis: a prospective pilot study

Optimization of shockwave lithotripsy use for single medium sized hard renal stone with stone density ≥ 1000 HU. A prospective study

A comparative study of peri-operative outcomes for 100 consecutive post-chemotherapy and primary robot-assisted and open retroperitoneal lymph node dissections

Study on the effect of rapid rehabilitation nursing in postoperative rehabilitation of PCNL patients

Ureteral reimplantation after deflux failure for vesicoureteral reflux in renal transplant